Author + information
- Yukihiko Momiyama, MDa (, )
- Reiko Hirano, PhDa,
- Hiroaki Taniguchi, MDa,
- Haruo Nakamura, MDa and
- Fumitaka Ohsuzu, MDa
We greatly appreciate the comments of Dr. Auer and colleagues regarding our article recently published in the Journal of the American College of Cardiology(1).
Chlamydia pneumoniae(CP) was often reported to be associated with coronary artery disease (CAD) in seroepidemiologic studies, but the potential contribution of CP to CAD remains controversial. As shown in our article (1), Auer et al. also found no significant difference in the CAD prevalence between patients with and without CP seropositivity. However, CP organism was detected within atheroma by direct immunofluorescence and polymerase chain reaction (PCR), and CP infection was shown to accelerate atherosclerosis in a rabbit model. We agree with Dr. Auer and colleagues that some triggers like cytokine gene polymorphisms or additional exposure to other pathogens could influence susceptibility to the atherogenic effect of CP infection.
Regarding genetic factors for CAD associated with CP infection, we reported that two polymorphisms of interleukin (IL)-1 genes play a role in the development of CAD, especially myocardial infarction, in patients with CP infection (1). However, other cytokine gene polymorphisms, such as IL-6 and IL-10, were also reported to be associated with CAD as well as inflammatory diseases. In addition to the IL-1 gene polymorphisms, they may be contributing to the development of CAD associated with CP infection. We will continue to seek genetic factors influencing the susceptibility to CAD associated with CP or other infections.
- American College of Cardiology Foundation